ID   CTLA4_HUMAN             Reviewed;         223 AA.
AC   P16410; A0N1S0; E9PDH0; O95653; Q0PP65; Q52MC1; Q53TD5; Q5S005; Q8WXJ1;
AC   Q96P43; Q9UKN9;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   10-JAN-2003, sequence version 3.
DT   28-JAN-2026, entry version 244.
DE   RecName: Full=Cytotoxic T-lymphocyte protein 4;
DE   AltName: Full=Cytotoxic T-lymphocyte-associated antigen 4;
DE            Short=CTLA-4;
DE   AltName: CD_antigen=CD152;
DE   Flags: Precursor;
GN   Name=CTLA4; Synonyms=CD152;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   ALTERNATIVE SPLICING, AND VARIANT ALA-17.
RX   PubMed=1713603;
RA   Harper K., Balzano C., Rouvier E., Mattei M.-G., Luciani M.-F.,
RA   Golstein P.;
RT   "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both
RT   mouse and human as to sequence, message expression, gene structure, and
RT   chromosomal location.";
RL   J. Immunol. 147:1037-1044(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11735222; DOI=10.1006/geno.2001.6655;
RA   Ling V., Wu P.W., Finnerty H.F., Agostino M.J., Graham J.R., Chen S.,
RA   Jussiff J.M., Fisk G.J., Miller C.P., Collins M.;
RT   "Assembly and annotation of human chromosome 2q33 sequence containing the
RT   CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative,
RT   and microarray approaches.";
RL   Genomics 78:155-168(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), VARIANT ALA-17,
RP   ALTERNATIVE SPLICING, AND POLYMORPHISM.
RX   PubMed=18595775; DOI=10.1016/j.clim.2008.05.006;
RA   Gu M., Kakoulidou M., Giscombe R., Pirskanen R., Lefvert A.K.,
RA   Klareskog L., Wang X.;
RT   "Identification of CTLA-4 isoforms produced by alternative splicing and
RT   their association with myasthenia gravis.";
RL   Clin. Immunol. 128:374-381(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wu P.W., Ling V.;
RT   "Full length sequence of hCTLA4 cDNA.";
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-223.
RC   TISSUE=Lymphocyte;
RX   PubMed=3220103; DOI=10.1002/eji.1830181206;
RA   Dariavach P., Mattei M.-G., Golstein P., Lefranc M.-P.;
RT   "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of
RT   protein sequence between murine and human CTLA-4 cytoplasmic domains.";
RL   Eur. J. Immunol. 18:1901-1905(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-223 (ISOFORM 5).
RC   TISSUE=Lymph node;
RA   Oaks M.K.;
RL   Submitted (FEB-1997) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 140-223, AND TISSUE SPECIFICITY.
RX   PubMed=10493833; DOI=10.1006/geno.1999.5930;
RA   Ling V., Wu P.W., Finnerty H.F., Sharpe A.H., Gray G.S., Collins M.;
RT   "Complete sequence determination of the mouse and human CTLA4 gene loci:
RT   cross-species DNA sequence similarity beyond exon borders.";
RL   Genomics 60:341-355(1999).
RN   [11]
RP   FUNCTION.
RX   PubMed=1714933; DOI=10.1084/jem.174.3.561;
RA   Linsley P.S., Brady W., Urnes M., Griosmaire L.S., Damle N.K.,
RA   Ledbetter J.A.;
RT   "CTLA-4 is a second receptor for the B cell activation antigen B7.";
RL   J. Exp. Med. 174:561-569(1991).
RN   [12]
RP   PHOSPHORYLATION AT TYR-201.
RX   PubMed=9175836; DOI=10.1016/s1074-7613(00)80346-5;
RA   Shiratori T., Miyatake S., Ohno H., Nakaseko C., Isono K., Bonifacino J.S.,
RA   Saito T.;
RT   "Tyrosine phosphorylation controls internalization of CTLA-4 by regulating
RT   its interaction with clathrin-associated adaptor complex AP-2.";
RL   Immunity 6:583-589(1997).
RN   [13]
RP   PHOSPHORYLATION AT TYR-201.
RX   PubMed=9813138; DOI=10.1006/bbrc.1998.9559;
RA   Schneider H., Schwartzberg P.L., Rudd C.E.;
RT   "Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and
RT   regulates PI 3-kinase binding to T-cell antigen CTLA-4.";
RL   Biochem. Biophys. Res. Commun. 252:14-19(1998).
RN   [14]
RP   PHOSPHORYLATION AT TYR-201 BY JAK2.
RX   PubMed=10842319;
RX   DOI=10.1002/(sici)1097-4644(20000801)78:2<241::aid-jcb7>3.3.co;2-b;
RA   Chikuma S., Murakami M., Tanaka K., Uede T.;
RT   "Janus kinase 2 is associated with a box 1-like motif and phosphorylates a
RT   critical tyrosine residue in the cytoplasmic region of cytotoxic T
RT   lymphocyte associated molecule-4.";
RL   J. Cell. Biochem. 78:241-250(2000).
RN   [15]
RP   POLYMORPHISM.
RX   PubMed=12724780; DOI=10.1038/nature01621;
RA   Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G.,
RA   Rainbow D.B., Hunter K.M., Smith A.N., Di Genova G., Herr M.H., Dahlman I.,
RA   Payne F., Smyth D., Lowe C., Twells R.C., Howlett S., Healy B., Nutland S.,
RA   Rance H.E., Everett V., Smink L.J., Lam A.C., Cordell H.J., Walker N.M.,
RA   Bordin C., Hulme J., Motzo C., Cucca F., Hess J.F., Metzker M.L.,
RA   Rogers J., Gregory S., Allahabadia A., Nithiyananthan R.,
RA   Tuomilehto-Wolf E., Tuomilehto J., Bingley P., Gillespie K.M.,
RA   Undlien D.E., Ronningen K.S., Guja C., Ionescu-Tirgoviste C., Savage D.A.,
RA   Maxwell A.P., Carson D.J., Patterson C.C., Franklyn J.A., Clayton D.G.,
RA   Peterson L.B., Wicker L.S., Todd J.A., Gough S.C.;
RT   "Association of the T-cell regulatory gene CTLA4 with susceptibility to
RT   autoimmune disease.";
RL   Nature 423:506-511(2003).
RN   [16]
RP   GLYCOSYLATION AT ASN-113 AND ASN-145.
RX   PubMed=16002699; DOI=10.4049/jimmunol.175.2.996;
RA   Darlington P.J., Kirchhof M.G., Criado G., Sondhi J., Madrenas J.;
RT   "Hierarchical regulation of CTLA-4 dimer-based lattice formation and its
RT   biological relevance for T cell inactivation.";
RL   J. Immunol. 175:996-1004(2005).
RN   [17]
RP   REVIEW.
RX   PubMed=16551244; DOI=10.1146/annurev.immunol.24.021605.090535;
RA   Teft W.A., Kirchhof M.G., Madrenas J.;
RT   "A molecular perspective of CTLA-4 function.";
RL   Annu. Rev. Immunol. 24:65-97(2006).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18641304; DOI=10.4049/jimmunol.181.3.1683;
RA   Zheng Y., Manzotti C.N., Burke F., Dussably L., Qureshi O., Walker L.S.,
RA   Sansom D.M.;
RT   "Acquisition of suppressive function by activated human CD4+ CD25- T cells
RT   is associated with the expression of CTLA-4 not FoxP3.";
RL   J. Immunol. 181:1683-1691(2008).
RN   [19]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18468488; DOI=10.1016/j.it.2008.02.011;
RA   Valk E., Rudd C.E., Schneider H.;
RT   "CTLA-4 trafficking and surface expression.";
RL   Trends Immunol. 29:272-279(2008).
RN   [20]
RP   PHARMACEUTICAL.
RX   PubMed=19426230; DOI=10.1111/j.1600-065x.2009.00780.x;
RA   Linsley P.S., Nadler S.G.;
RT   "The clinical utility of inhibiting CD28-mediated costimulation.";
RL   Immunol. Rev. 229:307-321(2009).
RN   [21]
RP   STRUCTURE BY NMR OF 37-161, AND DISULFIDE BONDS.
RX   PubMed=9228944; DOI=10.1038/nsb0797-527;
RA   Metzler W.J., Bajorath J., Fenderson W., Shaw S.Y., Constantine K.L.,
RA   Naemura J., Leytze G., Peach R.J., Lavoie T.B., Mueller L., Linsley P.S.;
RT   "Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding
RT   site conserved in CD28.";
RL   Nat. Struct. Biol. 4:527-531(1997).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD86,
RP   FUNCTION, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=11279501; DOI=10.1038/35069112;
RA   Schwartz J.C., Zhang X., Fedorov A.A., Nathenson S.G., Almo S.C.;
RT   "Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.";
RL   Nature 410:604-608(2001).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD80,
RP   FUNCTION, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-113 AND
RP   ASN-145.
RX   PubMed=11279502; DOI=10.1038/35069118;
RA   Stamper C.C., Zhang Y., Tobin J.F., Erbe D.V., Ikemizu S., Davis S.J.,
RA   Stahl M.L., Seehra J., Somers W.S., Mosyak L.;
RT   "Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune
RT   responses.";
RL   Nature 410:608-611(2001).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 38-161, DISULFIDE BONDS, AND
RP   SUBUNIT.
RA   Schonfeld D.L., Matschiner G., Chatwell L., Trentmann S., Schlehuber S.,
RA   Hohlbaum A., Skerra A.;
RT   "High affinity molecular recognition and functional blockade of CTLA-4 by
RT   an engineered human lipocalin.";
RL   Submitted (JAN-2008) to the PDB data bank.
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 36-161, GLYCOSYLATION AT ASN-113,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=21156796; DOI=10.1074/jbc.m110.182394;
RA   Yu C., Sonnen A.F., George R., Dessailly B.H., Stagg L.J., Evans E.J.,
RA   Orengo C.A., Stuart D.I., Ladbury J.E., Ikemizu S., Gilbert R.J.,
RA   Davis S.J.;
RT   "Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4
RT   (CTLA-4) receptor triggering.";
RL   J. Biol. Chem. 286:6685-6696(2011).
RN   [26] {ECO:0007744|PDB:5TRU}
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 37-154 IN COMPLEX WITH
RP   THERAPEUTIC ANTIBODY IPILIMUMAB, FUNCTION, SUBUNIT, INTERACTION WITH
RP   ICOSLG, SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE BONDS, AND MUTAGENESIS OF
RP   VAL-45; LEU-47; SER-49; ARG-70; LYS-130; GLU-132; TYR-139 AND ILE-143.
RX   PubMed=28484017; DOI=10.1073/pnas.1617941114;
RA   Ramagopal U.A., Liu W., Garrett-Thomson S.C., Bonanno J.B., Yan Q.,
RA   Srinivasan M., Wong S.C., Bell A., Mankikar S., Rangan V.S., Deshpande S.,
RA   Korman A.J., Almo S.C.;
RT   "Structural basis for cancer immunotherapy by the first-in-class checkpoint
RT   inhibitor ipilimumab.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E4223-E4232(2017).
RN   [27]
RP   VARIANT ALA-17, AND INVOLVEMENT IN T1D12.
RX   PubMed=9259273; DOI=10.1093/hmg/6.8.1275;
RA   Marron M.P., Raffel L.J., Garchon H.-J., Jacob C.O., Serrano-Rios M.,
RA   Martinez Larrad M.T., Teng W.-P., Park Y., Zhang Z.-X., Goldstein D.R.,
RA   Tao Y.-W., Beaurain G., Bach J.-F., Huang H.-S., Luo D.-F., Zeidler A.,
RA   Rotter J.I., Yang M.C.K., Modilevsky T., Maclaren N.K., She J.-X.;
RT   "Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4
RT   polymorphisms in multiple ethnic groups.";
RL   Hum. Mol. Genet. 6:1275-1282(1997).
RN   [28]
RP   POLYMORPHISM, AND INVOLVEMENT IN CELIAC3.
RX   PubMed=10189842; DOI=10.1136/gut.43.2.187;
RA   Djilali-Saiah I., Schmitz J., Harfouch-Hammoud E., Mougenot J.-F.,
RA   Bach J.-F., Caillat-Zucman S.;
RT   "CTLA-4 gene polymorphism is associated with predisposition to coeliac
RT   disease.";
RL   Gut 43:187-189(1998).
RN   [29]
RP   VARIANT ALA-17, AND INVOLVEMENT IN THYROID ASSOCIATED ORBITOPATHY.
RX   PubMed=10475192; DOI=10.1016/s0140-6736(99)01465-8;
RA   Vaidya B., Imrie H., Perros P., Dickinson J., McCarthy M.I.,
RA   Kendall-Taylor P., Pearce S.H.S.;
RT   "Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers
RT   susceptibility to thyroid associated orbitopathy.";
RL   Lancet 354:743-744(1999).
RN   [30]
RP   POLYMORPHISM, VARIANT ALA-17, AND INVOLVEMENT IN GRAVES DISEASE.
RX   PubMed=10924276; DOI=10.1006/mgme.2000.3007;
RA   Chistyakov D.A., Savost'anov K.V., Turakulov R.I., Petunina N.A.,
RA   Trukhina L.V., Kudinova A.V., Balabolkin M.I., Nosikov V.V.;
RT   "Complex association analysis of Graves disease using a set of polymorphic
RT   markers.";
RL   Mol. Genet. Metab. 70:214-218(2000).
RN   [31]
RP   VARIANT ALA-17.
RX   PubMed=10903931; DOI=10.1086/303059;
RA   Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
RA   Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
RA   Knowles J.A.;
RT   "Familial primary pulmonary hypertension (gene PPH1) is caused by mutations
RT   in the bone morphogenetic protein receptor-II gene.";
RL   Am. J. Hum. Genet. 67:737-744(2000).
RN   [32]
RP   POLYMORPHISM, AND INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS.
RX   PubMed=15138458; DOI=10.1038/sj.ejhg.5201214;
RA   Barreto M., Santos E., Ferreira R., Fesel C., Fontes M.F., Pereira C.,
RA   Martins B., Andreia R., Viana J.F., Crespo F., Vasconcelos C., Ferreira C.,
RA   Vicente A.M.;
RT   "Evidence for CTLA4 as a susceptibility gene for systemic lupus
RT   erythematosus.";
RL   Eur. J. Hum. Genet. 12:620-626(2004).
RN   [33]
RP   POLYMORPHISM, INVOLVEMENT IN SUSCEPTIBILITY TO HBV INFECTION, AND VARIANT
RP   ALA-17.
RX   PubMed=15452244; DOI=10.1128/jvi.78.20.11258-11262.2004;
RA   Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A.,
RA   Vlahov D., O'Brien S.J., Astemborski J., Thomas D.L.;
RT   "Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus
RT   infection.";
RL   J. Virol. 78:11258-11262(2004).
RN   [34]
RP   POLYMORPHISM, AND INVOLVEMENT IN CELIAC3.
RX   PubMed=15657618; DOI=10.1038/sj.ejhg.5201357;
RA   Hunt K.A., McGovern D.P.B., Kumar P.J., Ghosh S., Travis S.P.L.,
RA   Walters J.R.F., Jewell D.P., Playford R.J., van Heel D.A.;
RT   "A common CTLA4 haplotype associated with coeliac disease.";
RL   Eur. J. Hum. Genet. 13:440-444(2005).
RN   [35]
RP   POLYMORPHISM, AND INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS.
RX   PubMed=15688186; DOI=10.1007/s00439-004-1244-1;
RA   Lee Y.H., Harley J.B., Nath S.K.;
RT   "CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-
RT   analysis.";
RL   Hum. Genet. 116:361-367(2005).
RN   [36]
RP   POLYMORPHISM, INVOLVEMENT IN IDAIL, AND VARIANT IDAIL TRP-70.
RX   PubMed=25329329; DOI=10.1038/nm.3746;
RA   Schubert D., Bode C., Kenefeck R., Hou T.Z., Wing J.B., Kennedy A.,
RA   Bulashevska A., Petersen B.S., Schaeffer A.A., Gruening B.A., Unger S.,
RA   Frede N., Baumann U., Witte T., Schmidt R.E., Dueckers G., Niehues T.,
RA   Seneviratne S., Kanariou M., Speckmann C., Ehl S., Rensing-Ehl A.,
RA   Warnatz K., Rakhmanov M., Thimme R., Hasselblatt P., Emmerich F.,
RA   Cathomen T., Backofen R., Fisch P., Seidl M., May A., Schmitt-Graeff A.,
RA   Ikemizu S., Salzer U., Franke A., Sakaguchi S., Walker L.S., Sansom D.M.,
RA   Grimbacher B.;
RT   "Autosomal dominant immune dysregulation syndrome in humans with CTLA4
RT   mutations.";
RL   Nat. Med. 20:1410-1416(2014).
RN   [37]
RP   POLYMORPHISM, AND INVOLVEMENT IN IDAIL.
RX   PubMed=25213377; DOI=10.1126/science.1255904;
RA   Kuehn H.S., Ouyang W., Lo B., Deenick E.K., Niemela J.E., Avery D.T.,
RA   Schickel J.N., Tran D.Q., Stoddard J., Zhang Y., Frucht D.M., Dumitriu B.,
RA   Scheinberg P., Folio L.R., Frein C.A., Price S., Koh C., Heller T.,
RA   Seroogy C.M., Huttenlocher A., Rao V.K., Su H.C., Kleiner D.,
RA   Notarangelo L.D., Rampertaap Y., Olivier K.N., McElwee J., Hughes J.,
RA   Pittaluga S., Oliveira J.B., Meffre E., Fleisher T.A., Holland S.M.,
RA   Lenardo M.J., Tangye S.G., Uzel G.;
RT   "Immune dysregulation in human subjects with heterozygous germline
RT   mutations in CTLA4.";
RL   Science 345:1623-1627(2014).
CC   -!- FUNCTION: Inhibitory receptor acting as a major negative regulator of
CC       T-cell responses (PubMed:11279501, PubMed:11279502, PubMed:16551244,
CC       PubMed:1714933, PubMed:18641304, PubMed:28484017). Acts as a decoy
CC       receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80
CC       and CD86, is considerably stronger than the affinity of their cognate
CC       stimulatory coreceptor CD28 (PubMed:11279501, PubMed:11279502,
CC       PubMed:16551244, PubMed:1714933, PubMed:28484017).
CC       {ECO:0000269|PubMed:11279501, ECO:0000269|PubMed:11279502,
CC       ECO:0000269|PubMed:1714933, ECO:0000269|PubMed:18641304,
CC       ECO:0000269|PubMed:28484017, ECO:0000303|PubMed:16551244}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11279501, PubMed:11279502,
CC       PubMed:21156796, PubMed:28484017, Ref.24). Interacts with ICOSLG
CC       (PubMed:28484017). {ECO:0000269|PubMed:11279501,
CC       ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:21156796,
CC       ECO:0000269|PubMed:28484017, ECO:0000269|Ref.24}.
CC   -!- INTERACTION:
CC       P16410; P33681: CD80; NbExp=10; IntAct=EBI-1030991, EBI-1031024;
CC       P16410; P42081: CD86; NbExp=6; IntAct=EBI-1030991, EBI-1030956;
CC       P16410; Q4LDR2: CTXN3; NbExp=3; IntAct=EBI-1030991, EBI-12019274;
CC       P16410; P50851: LRBA; NbExp=3; IntAct=EBI-1030991, EBI-1052167;
CC       P16410; Q13021: MALL; NbExp=3; IntAct=EBI-1030991, EBI-750078;
CC       P16410; P27986: PIK3R1; NbExp=3; IntAct=EBI-1030991, EBI-79464;
CC       P16410; A2RU14: TMEM218; NbExp=3; IntAct=EBI-1030991, EBI-10173151;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18468488,
CC       ECO:0000269|PubMed:18641304, ECO:0000269|PubMed:28484017}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:18468488,
CC       ECO:0000269|PubMed:28484017}. Note=Exists primarily an intracellular
CC       antigen whose surface expression is tightly regulated by restricted
CC       trafficking to the cell surface and rapid internalization.
CC       {ECO:0000269|PubMed:18468488}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P16410-1; Sequence=Displayed;
CC       Name=2; Synonyms=ss-CTLA-4;
CC         IsoId=P16410-2; Sequence=VSP_041284;
CC       Name=3;
CC         IsoId=P16410-3; Sequence=VSP_041284, VSP_041287;
CC       Name=4;
CC         IsoId=P16410-4; Sequence=VSP_041285, VSP_041286, VSP_041287;
CC       Name=5;
CC         IsoId=P16410-5; Sequence=VSP_047238, VSP_047239;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in lymphoid
CC       tissues. Detected in activated T-cells where expression levels are
CC       30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell
CC       surface following activation. {ECO:0000269|PubMed:10493833,
CC       ECO:0000269|PubMed:1713603, ECO:0000303|PubMed:16551244}.
CC   -!- PTM: N-glycosylation is important for dimerization.
CC       {ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:16002699,
CC       ECO:0000269|PubMed:21156796}.
CC   -!- PTM: Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter
CC       complex, blocks endocytosis, and leads to retention of CTLA4 on the
CC       cell surface. {ECO:0000269|PubMed:10842319, ECO:0000269|PubMed:9175836,
CC       ECO:0000269|PubMed:9813138}.
CC   -!- POLYMORPHISM: Genetic variations in CTLA4 are associated with
CC       susceptibility to several autoimmune disorders (PubMed:10189842,
CC       PubMed:10924276, PubMed:12724780, PubMed:15138458, PubMed:15657618,
CC       PubMed:15688186, PubMed:18595775, PubMed:25213377, PubMed:25329329).
CC       They influence responsiveness to hepatitis B virus (HBV) infection
CC       [MIM:610424] (PubMed:15452244). {ECO:0000269|PubMed:10189842,
CC       ECO:0000269|PubMed:10924276, ECO:0000269|PubMed:12724780,
CC       ECO:0000269|PubMed:15138458, ECO:0000269|PubMed:15452244,
CC       ECO:0000269|PubMed:15657618, ECO:0000269|PubMed:15688186,
CC       ECO:0000269|PubMed:18595775, ECO:0000269|PubMed:25213377,
CC       ECO:0000269|PubMed:25329329}.
CC   -!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic,
CC       relapsing, inflammatory, and often febrile multisystemic disorder of
CC       connective tissue, characterized principally by involvement of the
CC       skin, joints, kidneys and serosal membranes. It is of unknown etiology,
CC       but is thought to represent a failure of the regulatory mechanisms of
CC       the autoimmune system. The disease is marked by a wide range of system
CC       dysfunctions, an elevated erythrocyte sedimentation rate, and the
CC       formation of LE cells in the blood or bone marrow.
CC       {ECO:0000269|PubMed:15138458, ECO:0000269|PubMed:15688186}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Note=Genetic variations in CTLA4 may influence susceptibility
CC       to Graves disease, an autoimmune disorder associated with overactivity
CC       of the thyroid gland and hyperthyroidism.
CC       {ECO:0000269|PubMed:10924276}.
CC   -!- DISEASE: Type 1 diabetes mellitus 12 (T1D12) [MIM:601388]: A
CC       multifactorial disorder of glucose homeostasis that is characterized by
CC       susceptibility to ketoacidosis in the absence of insulin therapy.
CC       Clinical features are polydipsia, polyphagia and polyuria which result
CC       from hyperglycemia-induced osmotic diuresis and secondary thirst. These
CC       derangements result in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:9259273}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Celiac disease 3 (CELIAC3) [MIM:609755]: A multifactorial,
CC       chronic disorder of the small intestine caused by intolerance to
CC       gluten. It is characterized by immune-mediated enteropathy associated
CC       with failed intestinal absorption, and malnutrition. In predisposed
CC       individuals, the ingestion of gluten-containing food such as wheat and
CC       rye induces a flat jejunal mucosa with infiltration of lymphocytes.
CC       {ECO:0000269|PubMed:10189842, ECO:0000269|PubMed:15657618}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Immune dysregulation with autoimmunity, immunodeficiency, and
CC       lymphoproliferation (IDAIL) [MIM:616100]: An autosomal dominant primary
CC       immunodeficiency characterized by severe autoimmunity, infiltration of
CC       non-lymphoid organs, such as the intestine, lungs and brain, by
CC       hyperactive T cells and B cells, autoimmune cytopenias, and
CC       hypogammaglobulinemia in early childhood. {ECO:0000269|PubMed:25213377,
CC       ECO:0000269|PubMed:25329329}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: Engineered fusion proteins consisting of the
CC       extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig), inhibit
CC       T-cell-dependent antibody responses, and are used as immunosuppressive
CC       agents. They are soluble, have an enhanced affinity for B7 ligands and
CC       act as a competitive inhibitor of CD28.
CC   -!- MISCELLANEOUS: The therapeutic antibody Ipilimumab competes for the
CC       binding site of the endogenous ligands CD80/B7-1, CD86/B7-2 and ICOSLG.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CLTA-4 entry;
CC       URL="https://en.wikipedia.org/wiki/CTLA-4";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L15006; AAB59385.1; -; mRNA.
DR   EMBL; M74363; AAA52127.1; -; Genomic_DNA.
DR   EMBL; AF411058; AAL40932.1; -; Genomic_DNA.
DR   EMBL; AY792514; AAV66331.1; -; mRNA.
DR   EMBL; AY999702; AAY00166.1; -; mRNA.
DR   EMBL; DQ785106; ABG85285.1; -; mRNA.
DR   EMBL; AF414120; AAL07473.1; -; mRNA.
DR   EMBL; DQ357942; ABC67470.1; -; Genomic_DNA.
DR   EMBL; AC010138; AAX93176.1; -; Genomic_DNA.
DR   EMBL; BC074842; AAH74842.1; -; mRNA.
DR   EMBL; BC074893; AAH74893.1; -; mRNA.
DR   EMBL; AH002733; AAA52773.1; -; Genomic_DNA.
DR   EMBL; U90273; AAD00698.1; -; mRNA.
DR   EMBL; AF142144; AAF02499.1; -; Genomic_DNA.
DR   CCDS; CCDS2362.1; -. [P16410-1]
DR   CCDS; CCDS42803.1; -. [P16410-5]
DR   PIR; S08614; S08614.
DR   RefSeq; NP_001032720.1; NM_001037631.3. [P16410-5]
DR   RefSeq; NP_005205.2; NM_005214.4. [P16410-1]
DR   PDB; 1AH1; NMR; -; A=37-161.
DR   PDB; 1H6E; X-ray; 3.60 A; P=197-207.
DR   PDB; 1I85; X-ray; 3.20 A; C/D=36-161.
DR   PDB; 1I8L; X-ray; 3.00 A; C/D=36-161.
DR   PDB; 2X44; X-ray; 2.60 A; D=36-161.
DR   PDB; 3BX7; X-ray; 2.10 A; C=38-161.
DR   PDB; 3OSK; X-ray; 1.80 A; A/B=36-161.
DR   PDB; 5GGV; X-ray; 2.00 A; Y=36-161.
DR   PDB; 5TRU; X-ray; 3.00 A; C/c=37-154.
DR   PDB; 5XJ3; X-ray; 3.20 A; C/F/I/L=36-161.
DR   PDB; 6RP8; X-ray; 2.60 A; C/c=37-154.
DR   PDB; 6RPJ; X-ray; 3.25 A; A/C/E/G=37-156.
DR   PDB; 6RQM; X-ray; 3.00 A; A=37-161.
DR   PDB; 6XY2; X-ray; 3.05 A; A=38-160.
DR   PDB; 7CIO; X-ray; 1.10 A; B=199-206.
DR   PDB; 7DV4; X-ray; 2.38 A; A/C/E/G=36-153.
DR   PDB; 7ELX; X-ray; 2.14 A; C/c=36-161.
DR   PDB; 7SU0; X-ray; 2.41 A; C/D=36-153.
DR   PDB; 7SU1; X-ray; 2.53 A; C=36-153.
DR   PDB; 8GAB; X-ray; 2.72 A; B/D=36-161.
DR   PDB; 8HIT; X-ray; 3.20 A; C=35-154.
DR   PDB; 9DQ3; X-ray; 1.64 A; C=36-153.
DR   PDBsum; 1AH1; -.
DR   PDBsum; 1H6E; -.
DR   PDBsum; 1I85; -.
DR   PDBsum; 1I8L; -.
DR   PDBsum; 2X44; -.
DR   PDBsum; 3BX7; -.
DR   PDBsum; 3OSK; -.
DR   PDBsum; 5GGV; -.
DR   PDBsum; 5TRU; -.
DR   PDBsum; 5XJ3; -.
DR   PDBsum; 6RP8; -.
DR   PDBsum; 6RPJ; -.
DR   PDBsum; 6RQM; -.
DR   PDBsum; 6XY2; -.
DR   PDBsum; 7CIO; -.
DR   PDBsum; 7DV4; -.
DR   PDBsum; 7ELX; -.
DR   PDBsum; 7SU0; -.
DR   PDBsum; 7SU1; -.
DR   PDBsum; 8GAB; -.
DR   PDBsum; 8HIT; -.
DR   PDBsum; 9DQ3; -.
DR   AlphaFoldDB; P16410; -.
DR   SMR; P16410; -.
DR   BioGRID; 107875; 134.
DR   DIP; DIP-35607N; -.
DR   ELM; P16410; -.
DR   FunCoup; P16410; 584.
DR   IntAct; P16410; 136.
DR   MINT; P16410; -.
DR   STRING; 9606.ENSP00000497102; -.
DR   BindingDB; P16410; -.
DR   ChEMBL; CHEMBL2364164; -.
DR   DrugBank; DB01281; Abatacept.
DR   DrugBank; DB06186; Ipilimumab.
DR   DrugBank; DB11771; Tremelimumab.
DR   DrugCentral; P16410; -.
DR   GuidetoPHARMACOLOGY; 2743; -.
DR   GlyCosmos; P16410; 2 sites, No reported glycans.
DR   GlyGen; P16410; 3 sites.
DR   iPTMnet; P16410; -.
DR   PhosphoSitePlus; P16410; -.
DR   BioMuta; CTLA4; -.
DR   DMDM; 27735177; -.
DR   MassIVE; P16410; -.
DR   PaxDb; 9606-ENSP00000303939; -.
DR   PeptideAtlas; P16410; -.
DR   ABCD; P16410; 206 sequenced antibodies.
DR   Antibodypedia; 19961; 2166 antibodies from 52 providers.
DR   CPTC; P16410; 3 antibodies.
DR   DNASU; 1493; -.
DR   Ensembl; ENST00000295854.10; ENSP00000295854.6; ENSG00000163599.18. [P16410-5]
DR   Ensembl; ENST00000487393.1; ENSP00000497319.1; ENSG00000163599.18. [P16410-3]
DR   Ensembl; ENST00000648405.2; ENSP00000497102.1; ENSG00000163599.18. [P16410-1]
DR   GeneID; 1493; -.
DR   KEGG; hsa:1493; -.
DR   MANE-Select; ENST00000648405.2; ENSP00000497102.1; NM_005214.5; NP_005205.2.
DR   UCSC; uc002vak.3; human. [P16410-1]
DR   AGR; HGNC:2505; -.
DR   CIViC; 1493; 1 evidence item across 1 molecular profile.
DR   ClinPGx; PA27006; -.
DR   CTD; 1493; -.
DR   DisGeNET; 1493; -.
DR   GeneCards; CTLA4; -.
DR   HGNC; HGNC:2505; CTLA4.
DR   HPA; ENSG00000163599; Tissue enriched (lymphoid).
DR   MalaCards; CTLA4; -.
DR   MIM; 109100; phenotype.
DR   MIM; 123890; gene.
DR   MIM; 152700; phenotype.
DR   MIM; 601388; phenotype.
DR   MIM; 609755; phenotype.
DR   MIM; 610424; phenotype.
DR   MIM; 616100; phenotype.
DR   OpenTargets; ENSG00000163599; -.
DR   Orphanet; 391490; Adult-onset myasthenia gravis.
DR   Orphanet; 436159; Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency.
DR   Orphanet; 2584; Classic mycosis fungoides.
DR   Orphanet; 900; Granulomatosis with polyangiitis.
DR   Orphanet; 3162; Sezary syndrome.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   VEuPathDB; HostDB:ENSG00000163599; -.
DR   eggNOG; ENOG502RZVK; Eukaryota.
DR   GeneTree; ENSGT00530000063873; -.
DR   HOGENOM; CLU_085095_0_0_1; -.
DR   InParanoid; P16410; -.
DR   OMA; QMVEVCA; -.
DR   OrthoDB; 9908091at2759; -.
DR   PAN-GO; P16410; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P16410; -.
DR   PathwayCommons; P16410; -.
DR   Reactome; R-HSA-389356; Co-stimulation by CD28.
DR   Reactome; R-HSA-389513; Co-inhibition by CTLA4.
DR   Reactome; R-HSA-8877330; RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs).
DR   SignaLink; P16410; -.
DR   SIGNOR; P16410; -.
DR   Agora; ENSG00000163599; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 1493; 6 hits in 1155 CRISPR screens.
DR   EvolutionaryTrace; P16410; -.
DR   GeneWiki; CTLA-4; -.
DR   GenomeRNAi; 1493; -.
DR   Pharos; P16410; Tclin.
DR   PRO; PR:P16410; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P16410; protein.
DR   Bgee; ENSG00000163599; Expressed in lymph node and 124 other cell types or tissues.
DR   GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProt.
DR   GO; GO:0098636; C:protein complex involved in cell adhesion; IDA:MGI.
DR   GO; GO:0140319; F:receptor decoy activity; IDA:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; IMP:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045590; P:negative regulation of regulatory T cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0050868; P:negative regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IDA:UniProt.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IBA:GO_Central.
DR   CDD; cd05721; IgV_CTLA-4; 1.
DR   FunFam; 2.60.40.10:FF:000686; Cytotoxic T-lymphocyte protein 4; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   InterPro; IPR008096; CTLA4.
DR   InterPro; IPR040216; CTLA4/CD28.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013106; Ig_V-set.
DR   PANTHER; PTHR11494; CYTOTOXIC T-LYMPHOCYTE PROTEIN; 1.
DR   PANTHER; PTHR11494:SF8; CYTOTOXIC T-LYMPHOCYTE PROTEIN 4; 1.
DR   Pfam; PF07686; V-set; 1.
DR   PRINTS; PR01720; CTLANTIGEN4.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00406; IGv; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Cell membrane;
KW   Diabetes mellitus; Disease variant; Disulfide bond; Glycoprotein; Immunity;
KW   Immunoglobulin domain; Membrane; Pharmaceutical; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Signal;
KW   Systemic lupus erythematosus; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..35
FT                   /evidence="ECO:0000255"
FT   CHAIN           36..223
FT                   /note="Cytotoxic T-lymphocyte protein 4"
FT                   /id="PRO_0000014734"
FT   TOPO_DOM        36..161
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:28484017"
FT   TRANSMEM        162..182
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        183..223
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          39..140
FT                   /note="Ig-like V-type"
FT   REGION          46..50
FT                   /note="Homodimerization"
FT                   /evidence="ECO:0000269|PubMed:21156796"
FT   REGION          134..139
FT                   /note="Important for interaction with CD80 and CD86"
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   REGION          150..155
FT                   /note="Homodimerization"
FT                   /evidence="ECO:0000269|PubMed:21156796,
FT                   ECO:0000269|PubMed:28484017"
FT   MOD_RES         201
FT                   /note="Phosphotyrosine; by TXK and JAK2"
FT                   /evidence="ECO:0000269|PubMed:10842319,
FT                   ECO:0000269|PubMed:9175836, ECO:0000269|PubMed:9813138"
FT   CARBOHYD        113
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11279502,
FT                   ECO:0000269|PubMed:16002699, ECO:0000269|PubMed:21156796"
FT   CARBOHYD        145
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11279502,
FT                   ECO:0000269|PubMed:16002699"
FT   DISULFID        58..129
FT                   /evidence="ECO:0000269|PubMed:11279501,
FT                   ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:21156796,
FT                   ECO:0000269|PubMed:28484017, ECO:0000269|PubMed:9228944,
FT                   ECO:0000269|Ref.24, ECO:0007744|PDB:3BX7,
FT                   ECO:0007744|PDB:5TRU"
FT   DISULFID        85..103
FT                   /evidence="ECO:0000269|PubMed:11279501,
FT                   ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:21156796,
FT                   ECO:0000269|PubMed:28484017, ECO:0000269|PubMed:9228944,
FT                   ECO:0000269|Ref.24, ECO:0007744|PDB:3BX7,
FT                   ECO:0007744|PDB:5TRU"
FT   DISULFID        157
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:28484017, ECO:0000269|Ref.24,
FT                   ECO:0007744|PDB:3BX7"
FT   VAR_SEQ         38..204
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18595775"
FT                   /id="VSP_041284"
FT   VAR_SEQ         58
FT                   /note="C -> S (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18595775"
FT                   /id="VSP_041285"
FT   VAR_SEQ         59..204
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18595775"
FT                   /id="VSP_041286"
FT   VAR_SEQ         153..174
FT                   /note="DPEPCPDSDFLLWILAAVSSGL -> AKEKKPSYNRGLCENAPNRARM (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|Ref.9"
FT                   /id="VSP_047238"
FT   VAR_SEQ         175..223
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.9"
FT                   /id="VSP_047239"
FT   VAR_SEQ         205..223
FT                   /note="PPTEPECEKQFQPYFIPIN -> KEKKPSYNRGLCENAPNRARM (in
FT                   isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18595775"
FT                   /id="VSP_041287"
FT   VARIANT         17
FT                   /note="T -> A (increased risk for Graves disease,
FT                   insulin-dependent diabetes mellitus, thyroid-associated
FT                   orbitopathy, systemic lupus erythematosus and
FT                   susceptibility to HBV infection; dbSNP:rs231775)"
FT                   /evidence="ECO:0000269|PubMed:10475192,
FT                   ECO:0000269|PubMed:10903931, ECO:0000269|PubMed:10924276,
FT                   ECO:0000269|PubMed:15452244, ECO:0000269|PubMed:1713603,
FT                   ECO:0000269|PubMed:18595775, ECO:0000269|PubMed:9259273"
FT                   /id="VAR_013577"
FT   VARIANT         70
FT                   /note="R -> W (in IDAIL; dbSNP:rs606231422)"
FT                   /evidence="ECO:0000269|PubMed:25329329"
FT                   /id="VAR_072681"
FT   MUTAGEN         45
FT                   /note="V->D: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         47
FT                   /note="L->D: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         49
FT                   /note="S->A: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         70
FT                   /note="R->A,D: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         130
FT                   /note="K->A,D: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         132
FT                   /note="E->A,R: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         139
FT                   /note="Y->A,D: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   MUTAGEN         143
FT                   /note="I->A,D: Strongly reduced interaction with CD80, CD86
FT                   and ICOSLG."
FT                   /evidence="ECO:0000269|PubMed:28484017"
FT   CONFLICT        37
FT                   /note="A -> V (in Ref. 3; ABG85285)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        147
FT                   /note="T -> A (in Ref. 8; AAA52773)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..41
FT                   /evidence="ECO:0007829|PDB:5GGV"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          50..52
FT                   /evidence="ECO:0007829|PDB:1I8L"
FT   STRAND          54..60
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          64..66
FT                   /evidence="ECO:0007829|PDB:1I85"
FT   STRAND          68..77
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          80..90
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   TURN            91..93
FT                   /evidence="ECO:0007829|PDB:6RP8"
FT   STRAND          95..99
FT                   /evidence="ECO:0007829|PDB:6RP8"
FT   STRAND          102..108
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          111..116
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   HELIX           121..123
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          125..138
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          140..143
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          147..150
FT                   /evidence="ECO:0007829|PDB:3OSK"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:1AH1"
SQ   SEQUENCE   223 AA;  24656 MW;  6F9466FB2E139A5A CRC64;
     MACLGFQRHK AQLNLATRTW PCTLLFFLLF IPVFCKAMHV AQPAVVLASS RGIASFVCEY
     ASPGKATEVR VTVLRQADSQ VTEVCAATYM MGNELTFLDD SICTGTSSGN QVNLTIQGLR
     AMDTGLYICK VELMYPPPYY LGIGNGTQIY VIDPEPCPDS DFLLWILAAV SSGLFFYSFL
     LTAVSLSKML KKRSPLTTGV YVKMPPTEPE CEKQFQPYFI PIN
//
